van Dijk K, Fischer K, van der Bom J G, Scheibel E, Ingerslev J, van den Berg H M
Van Creveldkliniek, UMC Utrecht, The Netherlands.
Br J Haematol. 2005 Jul;130(1):107-12. doi: 10.1111/j.1365-2141.2005.05546.x.
Prophylaxis is the treatment of choice for children with severe haemophilia. As prophylaxis is especially important during the period of growth, the need for continued prophylaxis in adulthood should be considered. The aim of this study was to describe the incidence and outcome of stopping prophylaxis in patients with severe haemophilia who were offered prophylaxis during childhood. All patients with severe haemophilia (factor VIII/IX <0.01 IU/ml), born 1970-80, treated in two Danish and one Dutch treatment centre were studied. Data on discontinuation of prophylaxis, treatment, joint bleed frequency, clinical scores and radiological scores were collected. Eighty patients were studied. Median follow-up was 19 years (range 7-29). A total of 35% of patients discontinued prophylaxis at a median age of 21.5 years [interquartile range (IQR) 18.4-24.4], experiencing only three joint bleeds per year (IQR 1.4-8.7). Median clinical scores were similar in patients who discontinued prophylaxis [4 points (IQR 0-6)] and those who continued [3 points (IQR 1-6)], as were median Pettersson scores at 13 (IQR 1-24) vs. 13 points (IQR 5-23) respectively. In conclusion one-third of young adults with severe haemophilia on a prophylactic regimen discontinued prophylaxis in early adulthood, while maintaining a low joint bleed frequency and similar arthropathy after 4 years.
预防性治疗是重度血友病患儿的首选治疗方法。由于预防性治疗在生长发育阶段尤为重要,因此应考虑成年后继续进行预防性治疗的必要性。本研究的目的是描述童年期接受预防性治疗的重度血友病患者停止预防性治疗的发生率和结果。对1970年至1980年出生、在两个丹麦治疗中心和一个荷兰治疗中心接受治疗的所有重度血友病患者(因子VIII/IX<0.01 IU/ml)进行了研究。收集了关于停止预防性治疗、治疗情况、关节出血频率、临床评分和放射学评分的数据。共研究了80例患者。中位随访时间为19年(范围7至29年)。共有35%的患者在中位年龄21.5岁时(四分位间距[IQR]18.4至24.4)停止预防性治疗,每年仅发生3次关节出血(IQR 1.4至8.7)。停止预防性治疗的患者中位临床评分为4分(IQR 0至6),继续预防性治疗的患者中位临床评分为3分(IQR 1至6),两者相似;Pettersson评分中位数分别为13分(IQR 1至24)和13分(IQR 5至23)。总之,三分之一接受预防性治疗方案的重度血友病青年成人在成年早期停止了预防性治疗,同时在4年后保持较低的关节出血频率和相似的关节病。